Sign up Australia
Proactive Investors - Run By Investors For Investors

Cash influx will help Redx develop promising pre-clinical drug candidates

It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
cancer cells
Both RXC004 and RXC005 should have started first-in-human trials by the end of 2017

Earlier this week Redx Pharma Plc (LON:REDX) unveiled plans to raise up to £14.9mln that will be used to develop two promising pre-clinical candidates.

Just under £7.2mln of that has already been raised in the first tranche of the fundraising, with more to come once the open offer is completed.

WATCH: CEO talks about funding this ‘critical phase’ of growth at Redx

The new cash injection will allow the company to push its highly promising cancer immunotherapy drug called a Porcupine inhibitor through early clinical studies to assess its safety.

The funds will also be used to carry out work that will make its Bruton's tyrosine kinase inhibitor “clinic-ready”.

Animal rescue?

Porcupine inhibitors are a new and potentially breakthrough method of fighting cancer.

They work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness.

The thinking goes that if you kill the stem cells, you have a chance of eradicating the disease completely.

There is a growing bank of research that has found they may also be very effective in tandem with checkpoint inhibitors such as anti-PD-1, which lower or break cancer’s defence against the body’s immune system.

That’s why Redx announced earlier this month that the upcoming trial of its RXC004 Porcupine inhibitor will assess the drug in combination with a checkpoint inhibitor as well as deploying it as a single treatment to tackle cancer.

Redx – which is currently finalising its clinical has said that the “combination arm” to the study reflects its “belief in the validity of this approach”.

So Redx, which is currently finalising its clinical trial application here in the UK, will build in a “combination arm” to the study, “reflecting our belief in the validity of this approach”.

As it stands, Swiss pharmaceutical giant is the only drug major with a Porcupine inhibitor in the clinic.

Looking at leukaemia as well

In addition to RXC004, Redx found another candidate from its cancer drug programme towards the end of 2016.

RXC005 – a Bruton’s tyrosine kinase inhibitor or BTK for short – is being designed for use in people with chronic lymphocytic leukaemia.

Importantly, it is also targeting those who have built up a resistance to the current best-in-class treatment, Imbruvica (often referred to as Ibrutinib).

The drug is being developed as a second-generation of compound which has fewer side-effects than the market leader.

Some of the £15mln Redx has just raised will be used to carry out work that will make RXC005 “clinic-ready”.

First-in-human trials are expected to get underway before 2017 is out.

What the boss says

“Redx has made tremendous progress since its IPO two years ago and 2017 should be a pivotal year as we transition to a clinical stage company,” said chief executive Neil Murray.

“We expect our Porcupine inhibitor, RXC004, to commence first-in-human trials within the next few months.  This compound shows exciting potential as a monotherapy for difficult to treat cancers, such as pancreatic, biliary and gastric cancer, and also as a combination therapy with Checkpoint inhibitors, which use the body's immune system to attack tumours.

“We are preparing our BTK inhibitor, RXC005, for first-in-human clinical trials by the end of the year.  This drug candidate has the potential to transform the treatment of patients with chronic lymphocytic leukaemia, the most common form of adult leukaemia.

“The new funds we are raising will support the ongoing progress of these important assets as well as the rest of our pipeline and we remain very positive about Redx's prospects.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

1513583223_shutterstock_86097949.jpg
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
spreadsheet and calculator
January 25 2018
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use